CJC-1295, ipamorelin, sermorelin, tesamorelin and other growth hormone secretagogues: how they work and what the research shows.
Genotropin · Norditropin · Humatrope · Omnitrope · Zomacton · Nutropin AQ · Serostim · Zorbtive · Sogroya · Skytrofa · Ngenla · Somatropin · Human growth hormone · HGH 191AA · rhGH · Recombinant human growth hormone
Recombinant human growth hormone (191-amino-acid protein) and long-acting growth hormone analogs
Recombinant human growth hormone, approved for growth hormone deficiency and a few rare conditions. Anti-aging use adds some lean mass but causes swelling and joint pain.
Read moreEgrifta · Egrifta SV · Egrifta WR · TH9507 · Tesamorelin acetate
Growth hormone-releasing hormone (GHRH) analog
An FDA-approved growth hormone-releasing hormone analog that reduces deep belly fat in adults with HIV-associated lipodystrophy.
Read moreGeref (discontinued) · GHRH (1-29) · Sermorelin acetate
Growth hormone-releasing hormone (GHRH) analog
A short GHRH analog that was FDA-approved for growth hormone deficiency in children, discontinued in 2008, and is now widely used by anti-aging clinics.
Read moreIpamorelin acetate · NNC 26-0161
Growth hormone secretagogue (ghrelin-receptor agonist)
A five-amino-acid ghrelin-receptor agonist that releases growth hormone. Never approved anywhere; its one published efficacy trial, in bowel surgery, failed.
Read moreCJC-1295 DAC · DAC:GRF
Growth hormone-releasing hormone (GHRH) analog
A long-acting growth hormone-releasing hormone analog. It raised growth hormone and IGF-1 for days in healthy adults, but development stopped in 2006.
Read moreIbutamoren · Ibutamoren mesylate · MK-0677 · L-163,191 · LUM-201
Oral ghrelin-receptor agonist (non-peptide growth hormone secretagogue)
An oral pill that mimics ghrelin to raise growth hormone. It added lean mass in older adults but raised blood sugar, and a trial was stopped over heart failure.
Read moreAOD9604 · Anti-Obesity Drug 9604 · Tyr-hGH (177-191)
Modified growth hormone fragment (16 amino acids)
A modified fragment of growth hormone developed in Australia as a fat-loss drug. It worked in obese mice, but its largest human trial found no weight loss.
Read moreLong R3 IGF-1 · LR3-IGF-I · LongR3 IGF-I · Long [Arg3] IGF-I · IGF-1 Long R3
Engineered recombinant IGF-1 analog (IGF-1 with arginine at position 3 and a 13-amino-acid N-terminal extension)
A lab-engineered, longer-acting version of IGF-1 made for cell culture and sold online for muscle growth. It has never been studied in humans and is banned in sport.
Read moreGrowth hormone releasing peptide-6 · GHRP6 · SK&F 110679 · His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Growth hormone secretagogue (ghrelin-receptor agonist)
The original growth hormone-releasing hexapeptide (1984). Raises growth hormone and hunger via the ghrelin receptor; not approved anywhere we found, and an FDA compounding safety risk.
Read moreGHRP Kaken 100 (Japan) · Pralmorelin · Pralmorelin hydrochloride · Growth hormone releasing peptide-2 · KP-102 · GPA-748
Growth hormone secretagogue (ghrelin-receptor agonist)
A ghrelin-receptor peptide sold in Japan since 2005 as a one-time diagnostic test for growth hormone deficiency. Raises hunger in people; we found no FDA approval.
Read moreExamorelin · His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2
Growth hormone secretagogue (ghrelin-receptor agonist); also binds CD36
A potent GHRP-6 analog that releases growth hormone, prolactin and cortisol. Its effect partly fades with daily use; studied for the heart, never approved.
Read morePegylated MGF · PEGylated mechano growth factor · Mechano growth factor pegylated · MGF E peptide · IGF-1Ec E peptide
Pegylated synthetic peptide derived from the E domain of IGF-1Ec (mechano growth factor)
A pegylated version of an IGF-1 splice variant peptide sold for muscle repair. It has never been tested in humans, and FDA has found no human exposure data.
Read more
GHRP-2 vs GHRP-6 vs hexarelin: human studies on growth hormone, hunger, cortisol, tolerance and FDA status, compared with ipamorelin and MK-677.
Why people stack tesamorelin and ipamorelin, what human studies of GHRH plus GHRP combinations show, why no trial has tested this pair, risks and legality.
What CJC-1295 without DAC and ipamorelin are, how the pair is meant to raise growth hormone, the research, side effects, doses and FDA status.
Hexarelin vs ipamorelin: one is a stronger growth hormone releaser that fades with daily use, the other is more selective. Human data, side effects, legality.
GHRP 2 vs ipamorelin compared: growth hormone potency, cortisol and prolactin effects, hunger, half-life, human trials, side effects and FDA status.
GHRP 6 side effects from human studies: hunger, cortisol and prolactin rises, flushing, blood sugar concerns, stroke-trial safety data and FDA's warnings.
GHRP 6 dosage in human studies: IV test doses of 0.1 to 1 mcg/kg, nasal and oral doses, stroke trial doses and what FDA says. No dose is approved.
Tesamorelin dosage from the Egrifta labels: 1.4 mg daily for Egrifta SV, 1.28 mg for Egrifta WR, how to inject, missed doses, monitoring and trial doses.
Sermorelin dosage explained: former Geref doses for children, the 0.5 to 2 mg doses tested in older men, injection timing, and why no dose is approved now.
Ipamorelin dosage in human studies: single IV doses of about 3 to 100 mcg/kg, and 0.03 mg/kg twice daily after surgery. No under-the-skin dose was tested.
MK-677 vs CJC-1295 ipamorelin: an oral ghrelin mimic vs an injected peptide pair. Human evidence, blood sugar and heart risks, side effects and FDA status.
CJC-1295 and ipamorelin side effects: flushing, headache, injection-site reactions, low potassium and high blood sugar in studies, plus FDA's safety concerns.
AOD-9604 dosage in human trials: 0.25 to 54 mg by mouth and 25 to 400 mcg/kg IV. No trial tested injections under the skin, and no dose beat placebo.
Tesamorelin results from clinical trials: 15% to 18% less deep belly fat, 37% less liver fat, little change in weight, and what happens after stopping.
CJC-1295 and ipamorelin dosage: no study has tested the pair. See the doses used for each peptide alone, why no-DAC has no dose data, and what to ask.
Ipamorelin vs tesamorelin: different receptors, half-lives and evidence. Tesamorelin is FDA-approved for HIV belly fat; ipamorelin's one published trial failed.
Sermorelin vs ipamorelin: a GHRH analog vs a ghrelin mimetic. How each releases growth hormone, the human evidence, side effects, FDA and compounding status.
Tesamorelin vs sermorelin: Egrifta is approved for HIV belly fat; sermorelin (Geref) was discontinued in 2008. Compare trials, side effects and compounding.
CJC-1295/ipamorelin vs tesamorelin: one is an FDA-approved drug with phase 3 trials, the other an untested, unapproved pair. Evidence and risks compared.
Do sermorelin tablets, troches and sublingual forms work? No study has tested them. What is known about oral and nasal sermorelin absorption.
Sermorelin side effects from clinical trials: flushing, injection-site pain, antibodies and blood sugar changes, plus what is unknown about long-term adult use.
Sermorelin results from published studies: growth in children, growth hormone and IGF-1 in older men, body composition, sleep, and before-and-after claims.
Ipamorelin side effects from its only published trial: low potassium, insomnia and high blood sugar, plus FDA safety concerns and unknowns about injections.
CJC-1295 and ipamorelin results: the hormone changes studies measured, the muscle, fat and sleep effects they never tested, and how to read before-and-afters.
AOD-9604 side effects in trials: headache, diarrhea and gas, plus chest tightness and euphoria after IV doses. FDA's concerns and what is still unknown.
GHRP 2 side effects from Japan's label and human studies: warmth, hunger, cortisol and prolactin rises, blood sugar concerns, and FDA's safety warnings.
GHRP 2 dosage in human studies: Japan's 100 mcg IV diagnostic test, research doses of 1 to 2 mcg/kg, and why no treatment dose has ever been approved.
CJC-1295 no DAC vs with DAC (mod GRF 1-29): how the albumin-binding DAC changes half-life, why only the DAC form has human data, and safety and legal status.
AOD-9604 results: it cut weight gain in obese mice and rats, but in the largest human trial of 502 adults, weight loss was no better than placebo.
Ipamorelin vs GHRP-6: both trigger growth hormone through the ghrelin receptor, but GHRP-6 drives hunger and stress hormones. Human data, safety and FDA status.
Peptides vs HGH: growth hormone-releasing peptides prompt your own release, while HGH replaces it. Compare evidence, side effects, legal status and uses.
CJC-1295 vs sermorelin: two GHRH analogs, one lasting days and one lasting minutes. Compare human studies, side effects, FDA history and compounding status.
FDA updates and new research, explained in 5 minutes. Every week, free.
Enter your email to get The Beginner's Guide to Peptides, a free 10-page PDF: what peptides are, why everyone's talking about them, the popular names, and how to read quality documents like a COA.
Download the guide (PDF)